Osborne Clarke advises iOnctura on its EUR 80 Million Series B Financing

Osborne Clarke has advised iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, on its EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund. 

Osborne Clarke also had the pleasure to assist iOnctura on its Series A financing round.

The Osborne Clarke core deal team consisted of Partner Herke van Hulst, Senior Associate Wouter Kok and Associate Angela Saldanha and further included partner/ civil-law notary Cars-Jan van Gool, Associate Femke Izendoorn and Tax partner Job van der Pol.